Brief: Acadia Pharmaceuticals Announces Trofinetide New Drug Submission Has Been Accepted For Filing And Priority Review By Health Canada
22/04/2024 14:08
April 22 (Reuters) - ACADIA Pharmaceuticals Inc
ACAD.O :
* ACADIA PHARMACEUTICALS ANNOUNCES TROFINETIDE NEW DRUG
SUBMISSION
FOR TREATMENT OF RETT SYNDROME HAS BEEN ACCEPTED FOR FILING AND
PRIORITY REVIEW BY HEALTH CANADA
Source text for Eikon: ID:nBw5b8Whla
Further company coverage: ACAD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study (updated)
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry